<DOC>
	<DOCNO>NCT01566162</DOCNO>
	<brief_summary>This 12-week , multi-center , open-label extension study design evaluate longer-term safety , tolerability effectiveness lurasidone treatment subject schizophrenia .</brief_summary>
	<brief_title>A Twelve Week , Open Label Extension Study Patients With Schizophrenia</brief_title>
	<detailed_description>This 12-week , multi-center , open-label extension study design evaluate longer-term safety , tolerability effectiveness lurasidone treatment subject schizophrenia participate Study D1050238 , double-blind , placebo-controlled , randomize withdrawal study lurasidone maintenance treatment subject schizophrenia . Subjects complete 28-week double-blind phase experience protocol-defined relapse event double-blind phase study D1050238 option participate study . In addition , if/when study discontinue sponsor , subject participate open-label phase double-blind phase study D1050238 option participate extension study</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Subject agree participate providing write informed consent . Subject eligible participate one follow criterion meet : Subject complete 28week doubleblind phase study D1050238 Subject experience protocoldefined relapse event double blind phase study D1050238 Subject participate openlabel doubleblind phase study D1050238 if/when study D1050238 terminate sponsor . Subject complete required assessment final study visit ( Study Visit Number 42 ) study D1050238 . Subject judge Investigator suitable participation 12week clinical trial involve openlabel lurasidone treatment able comply protocol opinion Investigator . Subject consider investigator imminent risk suicide injury self , others , property . Subject answer `` yes '' `` Suicidal Ideation '' item 4 ( active suicidal ideation intent act , without specific plan ) item 5 ( active suicidal ideation specific plan intent ) CSSRS extension baseline visit ( Study Visit Number 42 study D1050238 ) . Subjects answer `` yes '' question must refer Investigator appropriate followup evaluation treatment . Subject test positive drug abuse suspect current alcohol abuse extension baseline visit ( Study Visit Number 42 study D1050238 ) . In event subject test positive cannabinoids , Investigator evaluate subject 's ability abstain cannabis study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Lurasidone</keyword>
	<keyword>Latuda</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>